Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.
Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, McArthur G, Haydon A, Andrews MC, Cebon J, Guminski A, Kefford RF, Long GV, Menzies AM, Klein O, Carlino MS. Parakh S, et al. Among authors: cebon j. Br J Cancer. 2017 Jun 6;116(12):1558-1563. doi: 10.1038/bjc.2017.142. Epub 2017 May 18. Br J Cancer. 2017. PMID: 28524161 Free PMC article.
Cardiac metastases from malignant melanoma.
Gibbs P, Cebon JS, Calafiore P, Robinson WA. Gibbs P, et al. Among authors: cebon js. Cancer. 1999 Jan 1;85(1):78-84. Cancer. 1999. PMID: 9921977 Review.
Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.
Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, Mouritzen U, Hansen LT, Skak K, Lundsgaard D, Frederiksen KS, Kristjansen PE, McArthur G. Davis ID, et al. Among authors: cebon j. Clin Cancer Res. 2009 Mar 15;15(6):2123-9. doi: 10.1158/1078-0432.CCR-08-2663. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276257 Clinical Trial.
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
Nicholaou T, Ebert LM, Davis ID, McArthur GA, Jackson H, Dimopoulos N, Tan B, Maraskovsky E, Miloradovic L, Hopkins W, Pan L, Venhaus R, Hoffman EW, Chen W, Cebon J. Nicholaou T, et al. Among authors: cebon j. Clin Cancer Res. 2009 Mar 15;15(6):2166-73. doi: 10.1158/1078-0432.CCR-08-2484. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276262 Clinical Trial.
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.
Klein O, Ebert LM, Nicholaou T, Browning J, Russell SE, Zuber M, Jackson HM, Dimopoulos N, Tan BS, Hoos A, Luescher IF, Davis ID, Chen W, Cebon J. Klein O, et al. Among authors: cebon j. Clin Cancer Res. 2009 Apr 1;15(7):2507-13. doi: 10.1158/1078-0432.CCR-08-2424. Epub 2009 Mar 24. Clin Cancer Res. 2009. PMID: 19318477 Clinical Trial.
Melanoma vaccines: developments over the past 10 years.
Klein O, Schmidt C, Knights A, Davis ID, Chen W, Cebon J. Klein O, et al. Among authors: cebon j. Expert Rev Vaccines. 2011 Jun;10(6):853-73. doi: 10.1586/erv.11.74. Expert Rev Vaccines. 2011. PMID: 21692705 Review.
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Flaherty KT, et al. Among authors: cebon j. N Engl J Med. 2012 Nov 1;367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep 29. N Engl J Med. 2012. PMID: 23020132 Free PMC article. Clinical Trial.
304 results